SCHEMBL25218243

SCHEMBL25218243

CC(C)(N)CNC(=O)c1ccc(-c2cncc(-c3cncc(F)c3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 3/20 0.40
IKBKB O14920 1/20 0.39
TGFBR1 P36897 1/20 0.38
EGLN2 Q96KS0 1/20 0.38
PIK3CG P48736 1/20 0.38
AKR1C3 P42330 2/20 0.38
CYP17A1 P05093 1/20 0.38
FYN P06241 1/20 0.38
CHEK1 O14757 1/20 0.38
LIPC P11150 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
MAPT P10636 1/20 0.37
CHRM4 P08173 1/20 0.37
KDM1A O60341 1/20 0.37
HDAC1 Q13547 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
CLK1 P49759 1/20 0.36
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30438769 1.00 ULK1 (0.40) ULK1IKBKBTGFBR1EGLN2PIK3CG
Trifluoroacetic Acid SCHEMBL30439151 0.95 EGLN2 (0.41) ULK1IKBKBTGFBR1EGLN2AKR1C3
SCHEMBL25209962 0.87 EGLN2 (0.39) ULK1EGLN2AKR1C3CYP17A1FYN
SCHEMBL29253936 0.86 EGLN2 (0.38) ULK1EGLN2AKR1C3CYP17A1FYN
SCHEMBL25680207 0.83 LATS1 (0.39) ULK1EGLN2AKR1C3CYP17A1FYN
SCHEMBL30438994 0.79 DYRK1A (0.39) AKR1C3CHEK1CLK1DYRK1A
SCHEMBL25257863 0.79 DYRK1A (0.39) AKR1C3CHEK1CLK1DYRK1A
Hydrochloric Acid SCHEMBL30439503 0.78 DYRK1A (0.38) AKR1C3CYP17A1CHEK1CLK1DYRK1A
SCHEMBL25680124 0.78 P2RX7 (0.38) AKR1C3CYP17A1FYNDYRK1A
SCHEMBL25213710 0.78 DYRK1A (0.38) AKR1C3CHEK1TLR7DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122167-A1 Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-04-17 US claimed
EP-4436960-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GlaxoSmithKline Intellectual Property Development Limited (GB) 2024-10-02 EP claimed
WO-2023094305-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-01 WO claimed
US-20250122167-A1 Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-04-17 US disclosed
CN-118355005-A Pyrazine compounds for the treatment of parasitic protozoal infections 葛兰素史密斯克莱知识产权发展有限公司 2024-07-16 CN disclosed
WO-2023094305-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-01 WO disclosed
WO-2023094305-A1 PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122167-A1 Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection CYP3A5, CYP3A43, CYP51A1 ULK1 2047/4885IKBKB 3807/4885TGFBR1 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.